ReviewCurrent opinion in hematology2016
Transfusion-transmitted babesiosis: is it time to screen the blood supply?
Review in Current opinion in hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 71 citations in OpenAlex.
- Establishing, Maintaining, and Cryopreserving In Vitro Cultures of the Asexual Stages of Babesia divergens.Methods in molecular biology (Clifton, N.J.) · 2026Article
- In Vitro Monitoring of Babesia microti Infection Dynamics in Whole Blood Microenvironments.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Structural and Functional Characterization of the 28 kDa Structured Core of BmSA1, the Major Surface Antigen of Babesia Microti.Proteins · 2025Article
- Coinfection ofPathogens (Basel, Switzerland) · 2024Review
- Transmission risk evaluation of transfusion blood containing low-densityFrontiers in cellular and infection microbiology · 2024Article
- Role ofFrontiers in cellular and infection microbiology · 2024Article
- Supplemental findings of the 2021 National Blood Collection and Utilization Survey.Transfusion · 2023Article
- Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients.Pathogens (Basel, Switzerland) · 2023Review
- Is babesiosis a rare zoonosis in Spain? Its impact on the Spanish Health System over 23 years.PloS one · 2023Article
- HarnessingVaccines · 2022Review
- Sickle Cell Anemia andPathogens (Basel, Switzerland) · 2021Review
- Treatment of Human Babesiosis: Then and Now.Pathogens (Basel, Switzerland) · 2021Review
- Effective Therapy Targeting CytochromeAntimicrobial agents and chemotherapy · 2021Article
- Experimental Babesia rossi infection induces hemolytic, metabolic, and viral response pathways in the canine host.BMC genomics · 2021Article
- Nosocomial Infections: Do Not Forget the Parasites!Pathogens (Basel, Switzerland) · 2021Review
- Kinetic Characterization and Inhibitor Screening of Pyruvate Kinase I FromFrontiers in microbiology · 2021Article
- Rise in Babesiosis Cases, Pennsylvania, USA, 2005-2018.Emerging infectious diseases · 2020Article
- Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.Transfusion · 2020Review
- Emerging Tick-Borne Diseases.Clinical microbiology reviews · 2020Review
- Transfusion-associated adverse events and implementation of blood safety measures - findings from the 2017 National Blood Collection and Utilization Survey.Transfusion · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis review summarizes the current status of blood screening to prevent transfusion-transmitted babesiosis (TTB). RECENT
findingsBabesia microti has recently been determined to be the most common transfusion-transmitted pathogen in the United States. Patients who acquire TTB often experience severe illness with an associated mortality rate of about 20%. Recent studies have demonstrated that laboratory screening using B. microti antibody and/or PCR assays can effectively identify infectious blood donors and that this approach may offer a cost- effective means of intervention. Pathogen inactivation methods may offer an alternative solution. None of these methods has yet been licensed by US Food and Drug Administration, however, and current efforts to prevent TTB rely on excluding blood donors who report having had babesiosis. SUMMARY: TTB imposes a significant health burden on the United States population. Further research is needed to better inform decisions on optimal screening strategies and reentry criteria, but given the acute need and the currently available screening tools, initiation of blood donor screening to prevent TTB should be given high priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.